Glenmark and GBR401

by Savitha C Muppala on  April 1, 2011 at 8:30 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India.
 Glenmark and GBR401
Glenmark and GBR401

The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive